...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vojnosanitetski Pregled >The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation
【24h】

The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation

机译：玻璃体腔注射贝伐单抗对与年龄相关的黄斑变性伴肺泡下脉络膜新生血管的黄斑水肿和视敏度的影响

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim. Age-related macular degeneration (AMD) is a leading cause of the loss of central visual acuity in population older than 70 years. We can distinguish wet and dry form of AMD. The aim of the study was to present our early results in treatment of the wet (neovascular) form of AMD with intravitreal administration of bevacizumab. Methods. The study included 39 patients. Each patient underwent a complete ophthalmological examination, fluorescein angiography (FA) and optical coherence tomography (OCT). All the patients received 1.25 mg of intravitreal bevacizumab (0.05 mL of commercial phial of Avastin?). The total of three doses was given with a one-month interval between doses. Results. Among 39 patients, 24 were women and 15 men. The average best corrected visual acuity (BCVA) was improved from 0.09 before the therapy to 0.24 after the administration of all the three doses of bevacizumab (p
机译：背景/目标。年龄相关性黄斑变性（AMD）是70岁以上人群中枢视力丧失的主要原因。我们可以区分AMD的干湿两种形式。该研究的目的是介绍玻璃体腔注射贝伐单抗治疗湿性（新生血管）AMD的早期结果。方法。该研究包括39名患者。每位患者均接受了全面的眼科检查，荧光素血管造影（FA）和光学相干断层扫描（OCT）。所有患者均接受1.25毫克玻璃体内贝伐单抗（0.05毫升Avastin商业药瓶？）。总共给予三剂，每剂之间间隔一个月。结果。在39例患者中，女性为24例，男性为15例。平均最佳矫正视力（BCVA）从治疗前的0.09提高到所有三剂贝伐单抗给药后的0.24（p

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号